Boster Immunoleader

antibody

Anti-Osteoprotegerin Antibody

PA2118

100 ug/vial

200 USD

polyclonal

rabbit

human, mouse, rat

info changed 20150327

Anti-Osteoprotegerin Antibody

PA2118

Polyclonal

Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 11B(TNFRSF11B) detection. Tested with WB in Human;Mouse;Rat.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, rat Predicted to work with: mouse

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Rat; Predicted Species: Mouse

WB: The detection limit for TNFRSF11B is approximately 0.5ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the C-terminus of human Osteoprotegerin(369-389aa IRFLHSFTMYKLYQKLFLEMI), different from the related rat sequence by one amino acid, and different from the related mouse sequence by two amino acids.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

Tumor necrosis factor receptor superfamily member 11B(TNFRSF11B), also known as OPG, is a protein that in humans is encoded by the TNFRSF11B gene. OPG is a cytokine receptor, and a member of the tumor necrosis factor(TNF) receptor superfamily. By analysis of radiation hybrids, TNFRSF11B gene was mapped to chromosome 8q24. OPG is a decoy receptor for the receptor activator of nuclear factor kappa B ligand(RANKL). By binding RANKL, OPG inhibits nuclear kappa B(NF-kappa B) which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation. OPG binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and ostepclast precursors.

1. Krakauer T (2008). "Nuclear factor-kappa B: fine-tuning a central integrator of diverse biologic stimuli". Int. Rev. Immunol. 27 (5): 286–92. 2. Khosla S (December 2001). "Minireview: the OPG/RANKL/RANK system". Endocrinology 142 (12): 5050–5. 3. Schoppet M, Preissner KT, Hofbauer LC (April 2002). "RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function". Arterioscler. Thromb. Vasc. Biol. 22 (4): 549–53.

TNFRSF11B

Tumor necrosis factor receptor superfamily member 11B

tumor necrosis factor receptor superfamily, member 11b

MGC29565 antibody OCIF antibody OPG antibody Osteoclastogenesis inhibitory factor antibody Osteoprotegerin antibody TNFRSF 11B antibody TNFRSF11B antibody TR 1 antibody TR1 antibody TR11B_HUMAN antibody Tumor necrosis factor receptor superfamily member 11B antibody

O00300